New Drug for COPD: BREO ELLIPTA
This new medication is a combination inhaler that contains fluticasone furoate (an inhaled steroid) and vilanterol (a long acting beta-agonist bronchodilator).
Indication: Long term maintenance treatment for patients with COPD (chronic obstructive pulmonary disease), including chronic bronchitis and/or emphysema. It can reduce attacks of COPD in patients with a history of exacerbations.
It is NOT approved for treating asthma at this time, but many combination inhaled steroid/LABA medications are available for treating asthma. These include Advair (fluticasone proprionate + salmeterol), Symbicort (budesonide + formoterol) and Dulera (mometasone + formoterol).
What distinguishes BREO ELLIPTA from other combination inhalers?
- It is the only one approved for once a day use
- It comes as one dosing strength (fluticasone furoate 100 mcg/vilanterol 25 mcg).
- It is only available in a dry powder formulation.
- There is an increased risk of developing pneumonia (6-7%) compared to those on vilanterol alone (3%).
- Those persons with severe milk allergy should not use it.
What is similar to the other combination inhalers?
- It is not to be used for quick relief of symptoms.
- It has the “black box” warning about “asthma-related death.” This is placed on all LABA-containing medications.
- It is expensive (cash price $320 and up). However, there are coupons available at: http://www.goodrx.com/breo-ellipta
For more information on BREO ELLIPTA go to: http://www.mybreo.com/ This medication is made by GlaxoSmithKline.
At Family Allergy & Asthma Care of Montana, we bring you the latest pharmaceutical news that may impact your respiratory health.
This information is solely for informational purposes and not intended as a substitute for consultation with a medical professional.